FDA Panel Considers Dynavax’s Heplisav Safety Database Insufficient
This article was originally published in The Pink Sheet Daily
Executive Summary
The sponsor’s proposal for a post-approval cohort safety study in 30,000 patients failed to alleviate the concerns of a majority of the vaccines advisory committee, which voted 8 to 5 with one abstention that available data do not support the safety of the hepatitis B vaccine.
You may also be interested in...
Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says
FDA calls off November meeting to give 'more time to review and resolve several outstanding issues' with adjuvanted hepatitis B vaccine; Dynavax says agency determined meeting was not necessary to ensure regulatory decision by Dec. 15 goal date.
Dynavax Hep B Vaccine Gets Second Panel Review; Scrutiny On Safety, Superiority
After clinical hold, lost partnership and rejection by an advisory committee four years ago, Dynavax will again make its case for approval of Heplisav-B.
Heplisav’s Hopes For U.S. Approval Could Rest On Narrower Population
In a “complete response” letter for the novel, adjuvanted hepatitis B vaccine, FDA cites the need for more safety data in the broad population of adults for which approval was sought; however, Dynavax says the agency appears open to considering a more restricted use, such as in patients with chronic kidney disease.